“It has demonstrated strong efficacy in hidradenitis suppurativa, where Phase III is ongoing with data expected in 2027.”

In context

“with IGI Therapeutics. An interim analysis was recently completed on our monotherapy trial evaluating Lutikizumab in ulcerative colitis. Lutikizumab showed numerically higher efficacy for the primary endpoint of endoscopic improvement compared to HUMIRA, which was the control arm. However, the results were not sufficiently differentiated for us to pursue it as a monotherapy in this population. We believe there is still opportunity to drive incremental efficacy as a combination therapy in Crohn's disease, where Lutikizumab is being evaluated in combination with Skyrizi. Lutikizumab is one of several assets being studied and results from our Crohn's combination platform study will begin to read out next year. Lutikizumab has the potential to drive efficacy across other autoimmune diseases. It has demonstrated strong efficacy in hidradenitis suppurativa, where Phase III is ongoing with data expected in 2027. Additional studies are underway evaluating monotherapy or combination approaches in psoriatic arthritis, atopic dermatitis and rheumatoid arthritis. Moving to oncology. EMRELIS received accelerated approval from the FDA as a monotherapy in previously treated non-squamous non-small cell lung cancer with high c-Met expression. This is an important new treatment option for patients with this challenging disease. At the recent ASCO meeting, we presented encouraging data for several novel ADCs in our oncology pipeline, including preliminary data from a Phase I dose expansion study evaluating Temab-A, our next-generation c-Met ADC in patients with EGFR-mutated non-squamous non-small cell lung cancer. Temab-A demonstrated high and durable responses across c-MET expression levels with an objectiv”